Abstract: 23-Hydroxybetulinic acid (1) served as the precursor for the synthesis of C-28 ester derivatives. The target compounds were evaluated in vitro for their antitumor activities against five cell lines (A549, . Among the obtained compounds, 6i had the most potent antitumor activity, with the IC 50 values of 8.35 µM in HL-60 cells and showed similar antitumor activity as cyclophosphamide in H22 liver tumor and as 5-fluorouracil in B16 melanoma in vivo.
Introduction
23-Hydroxybetulinic acid (1, Figure 1 ) and betulinic acid (2, Figure1) are well-known members of the class of pentacyclic triterpenes [1, 2] . Many biological activities of betulinic acid have been reported, such as antitumor, antiviral, antioxidant and so on [3] [4] [5] [6] [7] [8] [9] . As a good lead compound, betulinic OPEN ACCESS acid showed potent antitumor activity in a series of cell lines and the mechanism of this action might be related to its effects on the proliferation, migration, cell cycle and apoptosis of tumor cells [3] [4] [5] [6] [7] [8] [9] .
The chemical structure of 23-hydroxybetulinic acid is similar to that of betulinic acid, and they also have the similar pharmaceutical activities [10] . In our previous study, many derivatives of 23-hydroxybetulinic acid showed antitumor activity in different cell lines in vitro and compound 3 ( Figure 1 ) displayed stronger antitumor activity in mice H22 and B16 than betulinic acid or 23-hydroxybetulinic acid [11] . It was shown that the polarity and length of the chain in C-28 had an important impact on the antitumor activity. These results motivated us to undertake further modifications of the 28-carboxylic acid moiety of lead compound 1. In this paper, we wish to report a series of 28-carboxylic acid modified 23-hydroxybetulinic acid ester derivatives and their antitumor activity. The preliminary structure-activity relationships are also discussed. 
Results and Discussion

Chemistry
For the synthetic experiments, the starting material 23-hydroxybetulinic acid (1) was isolated from the root of Pulsatilla chinensis. As described in Scheme 1, several derivatives of 23-hydroxybetulinic acid were synthesized. Compounds 5a-d were readily prepared in two steps starting from compound 1. Treatment of 5a-d with anhydrides R 2 (CO) 2 O, such as succinic anhydride, glutaric anhydride, maleic anhydride and phthalic anhydride, in the presence of DMAP in CH 2 Cl 2 gave compounds 6a-n in the yields of 53%-76%.
Biological Studies
The MTT (3-(4,5)dimethylthiahiazo (-z-y1) -3,5-diphenyltetrazoliumromide) assay results (Table 1) showed that most of the 23-hydroxybetulinic acid derivatives displayed better cytotoxic activities against the tested cells than betulinic acid and 23-hydroxybetulinic acid, especially compounds 6f, 6h, and 6i with IC 50 values ranging from 8.35 to 28.78 μM. As the assay results showed, C-28 ester derivatives with carboxylic acid substituents at the end of the C-28 side chain and whose C-28 side chain had appropriate length and flexibility exhibited stronger cytotoxicity. The activities of compounds 6k-n were weaker compared with 6f, 6h and 6i. It was possible due to the alkyne group in the C-28 side chain blocking the bending and rotation of the compounds. 
Compound 6i was chosen to evaluated its antitumor activities in mice in vivo based on its significant efficiency in vitro. As illustrated in Tables 2 and 3 , in H22 mice, compound 6i exhibited stronger activity than 23-hydroxybetulinic acid and comparable activity to cyclophosphamide, which was used as a positive control. In the B16 group, compound 6i also showed more potent activity than 23-hydroxybetulinic acid but somewhat weaker than 5-fluorouracil. 
Experimental
Synthesis
General
Melting points were obtained on a MEL-TEMP II melting-point apparatus and are uncorrected. IR were recorded on Nicolet Impact 410 or Bruker FT-IR TENSOR27 instruments. 1 H-NMR spectra were recorded on a Bruker-ACF-300 (chemical shifts are expressed as values relative to TMS as internal standard). HR-MS were obtained using a Agilent QTOF 6520 instrument.
General Procedure for the Synthesis of 6a-n
Ac 2 O (0.15 mL, 1.5 mmol) was added to a solution of 23-hydroxybetulinic acid (1, 120.0 mg, 0.25 mmol) in dry pyridine (5 mL). The mixture was stirred overnight at room temperature. After adding acetic ether (10 mL), the mixture was washed with 9% HCl (20 mL × 3) and brine (20 mL × 3), dried over anhydrous Na 2 SO 4 , filtered, and evaporated to dryness. The residue was purified by crystallization from ethyl acetate to afford the desired compound 4 as yellow powder (136.0 mg, 98%). (COCl) 2 (0.1 mL) was added to a solution of 4 (100.0 mg, 0.18 mmol) in dry CH 2 Cl 2 (10 mL). The mixture was stirred for 4 h at room temperature and evaporated to dryness. Immediately, the corresponding alcohol (5 equiv.) and CH 2 Cl 2 (10 mL) were added and the mixture allowed to stir for 8vh at room temperature, evaporated to dryness and purified by column chromatography on silica gel, eluted with an mixture of petroleum ether/ethyl acetate to give compounds 5a-d. The corresponding R 2 (CO) 2 O (4 equiv.) was added to a solution of compounds 5a-d in CH 2 Cl 2 (10 mL) in the presence of DMAP (1.5 equiv.). The mixture was stirred for 10 h at room temperature and washed with 9% HCl (20 mL × 2), H 2 O (20 mL × 2), brine (20 mL × 2), dried over anhydrous Na 2 SO 4 , filtered, and concentrated to dryness. The residue was purified by column chromatography on silica gel to afford compounds 6a-n. (25 mg/kg) in B16 group through intravenous injection in a vehicle of 20% DMSO/80% saline. The negative control group received 0.9% normal saline through intravenous injection. All test compounds were given through injections 24 h after tumor transplantation (or inoculation). Treatments were done at a frequency of intravenous or intraperitoneal injection one dose per day for a total of four consecutive days in H22 group and for a total of 11 consecutive days in B16 group. After the treatments, all mice were killed and weighed simultaneously, and then segregated and weighed the tumor [11] . Tumor inhibitory ratio was calculated by the following formula and perform T test:
Butylenedioic acid, 1-[2-[(3β,23-diacetoxylup-20(29)-en-28-oyl)oxy]ethyl] ester (6c
1,2-Xylenedioic acid, 1-[2-[(3β,23-diacetoxylup-20(29)-en-28-oyl)oxy]ethyl] ester (6d
Pentanedioic acid, 1-[4-[(3β,23-diacetoxylup-20(29)-en-28-oyl)oxy]ethyl] ester (6f)
.
1,2-xylenedioic acid, 1-[4-[(3β,23-diacetoxylup-20(29)-en-28-oyl)oxy]ethyl] ester (6g)
1,2-Xylenedioic acid, 1-[6-[(3β,23-diacetoxylup-20(29)-en-28-oyl)oxy]ethyl] ester (6j
Tumor inhibitory ratio (%) = (1-average tumor weight of treated group/average tumor weight of control group) × 100%
Conclusions
In summary, a series of novel of 23-hydroxybetulinic acid C-28 ester derivatives were synthesized and tested for their in vitro cytotoxic activities against five human tumor cell lines. Most of the compounds showed moderate potent cytotoxic activities on all the tested cells. The results of preliminary biological activity showed that three compounds (6f, 6h, 6i) possessed impressive cytotoxicities. Compound 6i was chosen to evaluate its antitumor activities in vivo. Compound 6i showed similar antitumor activity as cyclophosphamide in H22 and as 5-fluorouracil in B16. Further structure modification and SAR studies of antitumor 23-hydroxybetulinic acid derivatives are in progress in our laboratory and the results will be reported in due course [12] .
